health authority approval for AxisBiotix in France

SkinBioTherapeutics PLC

15 September 2023

 

 SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

AxisBiotix-Ps™ receives health authority approval for launch in France

·    Third European market to receive approval after Spain and Italy earlier in 2023

·    Marketing to customers to start in October 2023

·    Additional new geographical revenue stream

15 September 2023 - SkinBioTherapeutics plc (AIM: SBTX), a life science business focused on skin health, has announced that it has received approval from regulators to sell AxisBiotix-Ps™, a food supplement to alleviate the symptoms associated with Psoriasis, into the French market. Marketing of the product is expected to launch in France in October.

The announcement follows the launch of AxisBiotix-Ps^TM in Spain and Italy earlier this year, after prior authorisation was received in March and June respectively. Building on the initial launch in the UK where customer retention rates have remained above 80%,¹ the launch of AxisBiotix-Ps into another European market is the continuation of this commercialisation strategy.

Psoriasis is a common skin condition that effects 2-3% of the global population. There are as many as 2 million people suffering from psoriasis in France. Like other Western European countries, France has high rates of food supplement use, with one-third of respondents to a recent survey indicating they regularly use such supplements, and over half saying they had used them in the past year.²

The next target country for launch is to be confirmed, but the Company is in talks with other European regulatory agencies to expand the availability of AxisBiotix-Ps^TM.

Stuart J. Ashman, CEO of SkinBioTherapeutics, said: "In line with our strategic plan, we are delighted that AxisBiotix-Ps^TM is now approved for sale in another market, after the previous launches in the UK, Spain, and Italy. We anticipate an open reception from potential new customers in our European markets due to their positive attitude to food supplements. We have now completed the goal of launching in three major European markets in 2023 and we look forward to updating the market on other country launches next year."

Psoriasis is a lifelong condition, with no known cure, which impacts the everyday lives of sufferers. Existing treatments such as steroids or immuno-suppressants cannot be used over the long-term, which makes AxisBiotix-Ps™ an effective solution to alleviate its symptoms. As a food supplement, AxisBiotix-Ps™ is a food supplement that seeks to act on the gut-skin axis re-introducing missing bacteria into the gut and redressing the balance to improve skin health. The importance of the gut-skin axis is backed by strong scientific data.

1: Retention rates being measured as the number of subscribers who are remaining as a subscriber at the end of each month, compared to the same cohort that were in existence at the start of the previous month.
2: 'Baromètre 2022 de la consommation des compléments alimentaires en France', Synadiet, 10 March 2022, https://www.synadiet.org/app/uploads/2022/04/202111060_harris_interactive_rapport_barometre_conso_cpal_2022_v2.pdf

Change of Name of Nominated Adviser and Broker

The Company also announces that its Nominated Adviser and Sole Broker has changed its name to Cavendish Securities plc following completion of its own corporate merger.

-Ends-

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

For more information please contact:

SkinBioTherapeutics plc Stuart J. Ashman, CEO Manprit Randhawa, CFO	Tel: [phone]
Cavendish Securities Plc (Nominated Adviser & Broker) Giles Balleny, Charlie Combe (Corporate Finance) Dale Bellis, Tamar Cranford-Smith (Sales)	Tel: [phone]
Instinctif Partners (financial press) Melanie Toyne-Sewell / Tim Field / Adam Loudon	Tel: [phone] [e-mail]

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis.

The Company listed on AIM in April 2017 and is based in Newcastle, UK.

For more information, visit: www.skinbiotix.com and www.axisbiotix.com.

 

END